Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHDN 2022

What's new?

View all
3:35
Symptoms of juvenile onset Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
2:05
Tackling cognitive impairment in Huntington’s disease: a significant unmet need
Aaron Koenig • 22 Sep 2022
2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
1:34
EHDN 2022 meeting highlights
Patrick Weydt • 23 Sep 2022

Latest in the HD therapeutic pipeline

View all
5:38
PROOF-HD: Phase III trial of oral S1R agonist pridopidine for the treatment of Huntington’s disease
Michael Hayden • 27 Sep 2022
2:05
Tackling cognitive impairment in Huntington’s disease: a significant unmet need
Aaron Koenig • 22 Sep 2022

Hot topics: biomarkers

View all
2:06
Advancing mHTT as a biomarker in Huntington’s disease
Lauren Byrne • 23 Sep 2022
3:32
NfL as a potential biomarker for juvenile onset Huntington’s disease
Lauren Byrne • 23 Sep 2022
The content of VJNeurology is intended for healthcare professionals